Terms: = Colorectal cancer AND FAS, FAS1, 355, ENSG00000026103, FASTM, APO-1, P25445, CD95, ALPS1A, TNFRSF6, APT1 AND Treatment
253 results:
1. Discovery of Loureirin analogues with colorectal cancer suppressive activity via regulating cell cycle and fas death receptor.
Li P; Tian X; Zhang D; Ou H; Huang Q; Jin W; Liu R
BMC Pharmacol Toxicol; 2024 Jun; 25(1):36. PubMed ID: 38943212
[TBL] [Abstract] [Full Text] [Related]
2. Application of 18F-FDG PET/CT imaging radiomics in the differential diagnosis of single-nodule pulmonary metastases and second primary lung cancer in patients with colorectal cancer.
Yu Y; Zhu J; Sang S; Yang Y; Zhang B; Deng S
J Cancer Res Ther; 2024 Apr; 20(2):599-607. PubMed ID: 38687930
[TBL] [Abstract] [Full Text] [Related]
3. Inhibitory Effects of the Polyphenols from the Root of
Liang Y; Ban Y; Liu L; Li Y
Molecules; 2024 Mar; 29(5):. PubMed ID: 38474695
[TBL] [Abstract] [Full Text] [Related]
4. Negative Hyperselection of Resistance Mutations for Panitumumab Maintenance in RAS Wild-Type Metastatic colorectal cancer (PanaMa Phase II Trial, AIO KRK 0212).
Stahler A; Kind AJ; Sers C; Mamlouk S; Müller L; Karthaus M; Fruehauf S; Graeven U; Fischer von Weikersthal L; Sommerhäuser G; Kasper S; Hoppe B; Kurreck A; Held S; Heinemann V; Horst D; Jarosch A; Stintzing S; Trarbach T; Modest DP
Clin Cancer Res; 2024 Apr; 30(7):1256-1263. PubMed ID: 38289994
[TBL] [Abstract] [Full Text] [Related]
5. Effect of Hospital cancer Designation on use of Multimodal Therapy and Survival of Metastatic colorectal cancer: A State-Wide Analysis.
Meier J; Murimwa G; Nehrubabu M; DiMartino L; Singal AG; Karagkounis G; Yopp A; Zeh HJ; Polanco PM
Ann Surg Oncol; 2024 Apr; 31(4):2591-2597. PubMed ID: 38245645
[TBL] [Abstract] [Full Text] [Related]
6. Medical versus surgical causes of death following colorectal resection: a Queensland Audit of Surgical Mortality (QASM) study.
Mao D; Rey-Conde T; North JB; Lancashire RP; Naidu S; Chua T
ANZ J Surg; 2024 Apr; 94(4):684-690. PubMed ID: 38149760
[TBL] [Abstract] [Full Text] [Related]
7. Atovaquone inhibits colorectal cancer metastasis by regulating PDGFRβ/NF-κB signaling pathway.
Liu B; Zheng X; Li J; Yao P; Guo P; Liu W; Zhao G
BMC Cancer; 2023 Nov; 23(1):1070. PubMed ID: 37932661
[TBL] [Abstract] [Full Text] [Related]
8. Cost-utility analysis and cross-country comparison of pharmacogenomics-guided treatment in colorectal cancer patients participating in the U-PGx PREPARE study.
Fragoulakis V; Roncato R; Bignucolo A; Patrinos GP; Toffoli G; Cecchin E; Mitropoulou C
Pharmacol Res; 2023 Nov; 197():106949. PubMed ID: 37802427
[TBL] [Abstract] [Full Text] [Related]
9. Preconditioning of radiotherapy enhances efficacy of B7-H3-CAR-T in treating solid tumor models.
Wang T; Zhang K; You F; Ma R; Yang N; Tian S; An G; Yang L
Life Sci; 2023 Oct; 331():122024. PubMed ID: 37574043
[TBL] [Abstract] [Full Text] [Related]
10. FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line treatment of
Stintzing S; Heinrich K; Tougeron D; Modest DP; Schwaner I; Eucker J; Pihusch R; Stauch M; Kaiser F; Kahl C; Karthaus M; Müller C; Burkart C; Reinacher-Schick A; Kasper-Virchow S; Fischer von Weikersthal L; Krammer-Steiner B; Prager GW; Taieb J; Heinemann V
J Clin Oncol; 2023 Sep; 41(25):4143-4153. PubMed ID: 37352476
[TBL] [Abstract] [Full Text] [Related]
11. ELAPOR1 suppresses tumor progression in colorectal cancer and indicates favorable prognosis.
Huang A; Qin C; Wu M; Zhang D; Wu G; Sun P
Cancer Biomark; 2023; 37(4):279-288. PubMed ID: 37334577
[TBL] [Abstract] [Full Text] [Related]
12. An MRI Deep Learning Model Predicts Outcome in Rectal cancer.
Jiang X; Zhao H; Saldanha OL; Nebelung S; Kuhl C; Amygdalos I; Lang SA; Wu X; Meng X; Truhn D; Kather JN; Ke J
Radiology; 2023 Jun; 307(5):e222223. PubMed ID: 37278629
[TBL] [Abstract] [Full Text] [Related]
13. Enhanced anti-cancer effect of artemisinin- and curcumin-loaded niosomal nanoparticles against human colon cancer cells.
Firouzi Amandi A; Jokar E; Eslami M; Dadashpour M; Rezaie M; Yazdani Y; Nejati B
Med Oncol; 2023 May; 40(6):170. PubMed ID: 37156929
[TBL] [Abstract] [Full Text] [Related]
14. Consensus Molecular Subtypes as Biomarkers of Fluorouracil and Folinic Acid Maintenance Therapy With or Without Panitumumab in
Stahler A; Hoppe B; Na IK; Keilholz L; Müller L; Karthaus M; Fruehauf S; Graeven U; Fischer von Weikersthal L; Goekkurt E; Kasper S; Kind AJ; Kurreck A; Alig AHS; Held S; Reinacher-Schick A; Heinemann V; Horst D; Jarosch A; Stintzing S; Trarbach T; Modest DP
J Clin Oncol; 2023 Jun; 41(16):2975-2987. PubMed ID: 37018649
[TBL] [Abstract] [Full Text] [Related]
15. Effect of Different Durations of Adjuvant Capecitabine Monotherapy on the Outcome of High-Risk Stage II and Stage III colorectal cancer: A Retrospective Study Based on a CRC Database.
Yu Q; Li Z; Liu Y; Luo Y; Fan J; Xie P; Cao X; Chen X; Wang X
Curr Oncol; 2023 Jan; 30(1):949-958. PubMed ID: 36661721
[TBL] [Abstract] [Full Text] [Related]
16. Impact of Total Neoadjuvant Therapy on Postoperative Outcomes After Proctectomy for Rectal cancer.
Xu Z; Valente MA; Sklow B; Liska D; Gorgun E; Kessler H; Rosen DR; Steele SR
Dis Colon Rectum; 2023 Jul; 66(7):1022-1028. PubMed ID: 36538720
[TBL] [Abstract] [Full Text] [Related]
17. Low incidence of pelvic sepsis following Hartmann's procedure for rectal cancer: a retrospective multicentre study.
Mariusdottir E; Jörgren F; Mondlane A; Wikström J; Lydrup ML; Buchwald P
BMC Surg; 2022 Dec; 22(1):421. PubMed ID: 36494661
[TBL] [Abstract] [Full Text] [Related]
18. Dioscin reduced chemoresistance for colon cancer and analysis of sensitizing targets.
Li R; Qin J; Wang Z; Lv F; Guo J; Zhu H; Huang Y
Biochem Biophys Res Commun; 2023 Jan; 638():94-102. PubMed ID: 36442237
[TBL] [Abstract] [Full Text] [Related]
19. LY6G6D is a selectively expressed colorectal cancer antigen that can be used for targeting a therapeutic T-cell response by a T-cell engager.
Corrales L; Hipp S; Martin K; Sabarth N; Tirapu I; Fuchs K; Thaler B; Walterskirchen C; Bauer K; Fabits M; Bergmann M; Binder C; Chetta PM; Vogt AB; Adam PJ
Front Immunol; 2022; 13():1008764. PubMed ID: 36159851
[TBL] [Abstract] [Full Text] [Related]
20. First-line fluoropyrimidine plus bevacizumab followed by irinotecan-escalation versus initial fluoropyrimidine, irinotecan and bevacizumab in patients with metastatic colorectal cancer - Final survival and per-protocol analysis of the randomised XELAVIRI trial (AIO KRK 0110).
Stahler A; Modest DP; Fischer von Weikersthal L; Kaiser F; Decker T; Held S; Graeven U; Schwaner I; Denzlinger C; Schenk M; Kurreck A; Heinrich K; Gießen-Jung C; Neumann J; Kirchner T; Jung A; Stintzing S; Heinemann V
Eur J Cancer; 2022 Sep; 173():194-203. PubMed ID: 35940054
[TBL] [Abstract] [Full Text] [Related]
[Next]
